25-Mar-2019Media release

Kazia to present on Cantrixil at AACR 2019 meeting

25 March 2018: Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting.


AACR’s Annual Meeting is one of the top-tier academic conferences worldwide and brings together around 20,000 representatives from academia, industry, government and advocacy organisations from across the globe. The meeting is being held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA.


Clinical Program Director, Daniel Berg will be presenting on Kazia’s Cantrixil Phase I in ovarian cancer at the event on 1 April 2019. Mr Berg will present data from Part A of the study – the dose escalation component – which completed recruitment in October 2018.


TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. It was developed in Australia and initial preclinical studies were conducted at Yale University. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.


The abstract presentation is entitled: Phase I Study of Intraperitoneal TRX-E-002-1 in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer: Results of Dose-Escalation Phase.


The abstract has been authored by the trial’s Principal Investigators (PIs) - led by the two primary PIs in Australia and the US: Associate Professor Jermaine Coward at the ICON Cancer Care in Brisbane, Queensland and Dr Don Dizon at the Lifespan Cancer Institute at Rhode Island Hospital. The trial is being conducted across six sites in the US and Australia as follows:


  • Lifespan Cancer Institute, Providence, Rhode Island, USA under the oversight of Principal Investigator, Dr Dion Dizon
  • Stephenson Cancer Centre, Oklahoma, Oklahoma City, USA under the oversight of Principal Investigator, Assoc. Prof. Kathleen Moore
  • Mary Crowley Cancer Research Centre, Dallas, USA under the oversight of Principal Investigator, Dr. Minal Barve
  • ICON Cancer Care, Brisbane, Queensland, Australia under the oversight of Principal Investigator, Assoc. Prof Jermaine Howard
  • Westmead Hospital Sydney, New South Wales, Australia, under the oversight of Principal Investigator, Prof. Paul Harnett
  • Flinders Medical Centre, South Australia, under the oversight of Dr. Ganessan Kichenadasse


“The key objective with Part A of the Phase I study was to assess the safety of the drug and find the right dose level to take the study to the next stage. We are delighted to be presenting our data at the AACR meeting and we look forward to discussing our findings with clinicians and potential partners,” said Cantrixil Program Director Daniel Berg.


The presentation session details are as follows:

Session Title: Phase I Clinical Trials: Part 3
Date and Time: Monday April 1, 2019 1:00 PM - 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16
Poster Board Number: 15
Permanent Abstract Number: CT091


Interested parties are encouraged to attend and can add the session to their itinerary here: https://www.abstractsonline.com/pp8/#!/6812/session/1315

Meanwhile, the link to the abstract is here: https://www.abstractsonline.com/pp8/#!/6812/presentation/9899


The content of the abstract and presentation is embargoed until the start of the conference when it will be available through the above link and on the Kazia website.



Media contact: Gabriella Hold, gabriella.hold@irdepartment.com.au, +61 411 364 382 
For more information on Kazia Therapeutics or Cantrixil, please visit: www.kaziatherapeutics.com 


About Cantrixil Clinical Program Director, Daniel Berg


Daniel is a Program Director with 20 years’ experience working within the life sciences industry across small biotechs, Clinical Research Organisations and large multinational pharmaceutical companies including Eli Lilly, ICON, Pharmaxis and Sanofi. 


Starting his career as a Medicinal Chemist in the UK developing Tyrosine Kinase inhibitors for Celltech Therapeutics, Daniel has progressed his journey through the drug development lifecycle with varied affiliate, regional and global roles from Research and Development, through Clinical Development, Medical Affairs, along to Commercialisation and Corporate Project Management.  


With a degree in Medicinal Chemistry from the University of Sussex in the UK, Daniel has spent the majority of his career focusing on Program Management, delivering on projects across geographic, cultural and functional boundaries. During his time Daniel has been responsible for the delivery of global strategic planning and budgeting frameworks, organisational evolution to enable greater patient and customer centric focus, and major outsourcing programs along with new medicine and device clinical development and multi-country clinical research programs.